| Literature DB >> 24748894 |
Seiyed Mohammad Ali Ghayumi1, Abolfazl Khalafi-Nezhad1, Zahra Jowkar2.
Abstract
BACKGROUND: Liver transplant is the only definitive treatment for many patients with end stage liver disease. Presence and severity of preoperative pulmonary disease directly affect the rate of postoperative complications of the liver transplantation. Arterial blood gas (ABG) measurement, performed in many transplant centers, is considered as a traditional method to diagnose hypoxemia. Because ABG measurement is invasive and painful, pulse oximetry, a bedside, noninvasive and inexpensive technique, has been recommended as an alternative source for the ABG measurement.Entities:
Keywords: Blood Gas Monitoring, Transcutaneous; Liver Cirrhosis; Liver Transplantation; Oximetry; hypoxemia
Year: 2014 PMID: 24748894 PMCID: PMC3989597 DOI: 10.5812/hepatmon.15449
Source DB: PubMed Journal: Hepat Mon ISSN: 1735-143X Impact factor: 0.660
Demographics and Laboratory Data of the Patients [a,b]
| Variable | Value |
|---|---|
|
| 43.5 ± 13.7 |
|
| 237/153 |
|
| 18.3 ± 5.2 |
|
| |
| Cryptogenic | 99 (25.4) |
| Hepatitis B | 91 (23.3) |
| Autoimmune hepatitis | 43 (11) |
| Hepatitis C | 40 (10.3) |
| Primary sclerosing cholangitis | 39 (10) |
| Nonalcoholic fatty liver | 30 (7.7) |
| Alcoholic cirrhosis | 8 (2) |
| Wilson | 5 (1.3) |
| Miscellaneous | 35 (9) |
|
| 21.6 |
|
| |
| Normal | 57.4 |
| Restrictive | 33.3 |
| Obstructive | 7.5 |
| Mixed | 1 |
| Not available | 0.8 |
a Data are presented as mean ± SD, No. (%) or %.
b Abbreviations: MELD, model for End-Stage Liver Disease.
ABG and Pulse Oximetry Results and Calculated Bias [a]
| Measurement | Mean ± SD | Range | 95% CI |
|---|---|---|---|
|
| 7.46 ± 0.44 | 7.31-7.60 | 7.46-7.47 |
|
| 77.13 ± 13.85 | 40-100 | 75.68-78.58 |
|
| 29.28 ± 4.85 | 17-46 | 28.7-29.7 |
|
| 21.01 ± 3.49 | 10-31 | 20.6-21.3 |
|
| 95.19 ± 3.22 | 74-99 | 94.8-95.5 |
|
| 96.1 ± 2.96 | 80-100 | 95.8-96.4 |
|
| 1.48 ± 2.85 | -7-14 | 1.20-1.77 |
a Abbreviation: CI, confidence interval.
Figure 1.ROC Curves of SpO2 Measurement for the Detection of SpO2 < 60 mm Hg and SpO2 < 70 mmHg
Test Performance Characteristics of SpO2Measurement as Screening Tool for Hypoxemia
| SpO2 “positive” ≤ to | PaO2 < 70 mm Hg, sensitivity [%]/specificity[%] | PaO2 < 60 mm Hg, sensitivity [%]/specificity[%] |
|---|---|---|
|
| 9/100 | 17/100 |
|
| 12/100 | 23/100 |
|
| 22/99.3 | 41/99 |
|
| 36/99 | 67/98 |
|
| 47/98 | 87/97 |
|
| 55/97 | 97/96 |
|
| 61/96 | 100/95 |
|
| 68/91 | 100/89 |
|
| 86/79 | 100/73 |
|
| 100/46 | 100/41 |
|
| 100/8 | 100/8 |
|
| 100/1 | 100/1 |
|
| 100/0 | 100/0 |
Test Performance Characteristics of SpO2 Measurement as Screening Tool for Detection of Hypoxemia Based on the MELD Score [a]
| SpO2 “Positive” ≤ to | PaO2 < 60 mm Hg,Sensitivity [%]/Specificity[%] MELD < 20 | PaO2 < 60 mm Hg, Sensitivity [%]/Specificity[%] MELD ≥ 20 |
|---|---|---|
|
| 25/100 | 21/100 |
|
| 37/100 | 47/98 |
|
| 66/99 | 68/98 |
|
| 85/98 | 89/97 |
|
| 96/97 | 100/95 |
|
| 100/95 | 100/92 |
|
| 100/90 | 100/88 |
|
| 100/72 | 100/74 |
|
| 100/41 | 100/41 |
|
| 100/8 | 100/8 |
|
| 100/2 | 100/5 |
|
| 100/0 | 100/0 |
a Abbreviation: MELD, model for End-Stage Liver Disease.